ERBB2 and gastric cancer: The remarkable performance of T-DXd in the DESTINY-Gastric01 study, in stark contrast to the results of the GATSBY trial (38), showcased the profound potential of the next-generation ADC platform to overcome resistance to existing HER2-targeted therapies, heralding a new era in the treatment of HER2-positive GC.